FlandersBio on Twitter

Follow us on Twitter

management - News

management - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

TiGenix participates in key conferences in the first half of 2016

08.01.2016

TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today the key conferences in which it is going to participate during the first half of 2016. read more

ABLYNX TO PRESENT AT THE 34th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

07.01.2016

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it will present at the 34th Annual J.P. Morgan Healthcare Conference on Thursday 14 January 2016 at 10:30 a.m. Pacific Standard Time (07:30 p.m. Central Eastern Time). read more

Genticel appoints Rémi Palmantier, PhD, as Chief Scientific Officer to accelerate its development

06.01.2016

Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), today announces the appointment of a seasoned scientist with broad international experience, Rémi Palmantier, PhD, as Chief Scientific Officer. read more

Celyad announces the appointment of Dr. Jean-Pierre Latere as Head of the Regenerative Medicine and Medical Device Franchise

04.01.2016

Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced the appointment of Dr. Jean-Pierre Latere as Head of the Regenerative Medicine and Medical Device Franchise, effective January 4th, 2016. read more

Celyad to address US institutional investors in January at J.P. Morgan Healthcare Conference

23.12.2015

Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced its participation to the 34th edition of the annual J.P. Morgan Healthcare Conference which will be held from 11 to 15 January 2016 in San Francisco. read more

ESPERITE N.V. issues convertible loan to CEO Frédéric Amar

23.12.2015

ESPERITE N.V. (Euronext: ESP, 'ESPERITE', or 'the Group') announces the issuance of a convertible loan note of EUR 925,565 to Mr. Frédéric Amar, ESPERITE's Chief Executive Officer and largest shareholder. The issuance converts a payment obligation that ESPERITE has towards Mr. Amar relating to remuneration and pre-paid investments and expenses into the note. Mr. Amar has not participated in the decision-making of the Board of Directors regarding the issuance of the note. read more

Jan De Backer CEO van FLUIDDA - ‘CEO of the month’ voor de toonaangevende financiële groep ‘Aquisition International’

07.12.2015

‘Acquisition International magazine’ informeert wereldwijd meer dan 53.000 beslissers met intelligente overzichten en financiële analyses van verschillende markten. Ze verkozen Jan De Backer, CEO van FLUIDDA, tot CEO van de maand. read more

Celyad announces the appointment of Pierre Brynaert as Chief Human Resources Officer

07.12.2015

Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced the appointment of Pierre Brynaert as Chief Human Resources Officer, effective January 4, 2016. read more

VIB cordially invites you to the keynote talk of Aaron Mackey on 11th of December 2015

07.12.2015

Aaron Mackey will talk about the concept of HemoShere Therapeutics Ltd and the use of modelling to accurately predict drug side effects in a vascular model. read more

Benedikt Timmerman resumes CEO position at Genticel

03.12.2015

Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), announces that after meeting yesterday, the Company’s Supervisory Board has reappointed Benedikt Timmerman, founder and member of the Executive Management Board, as CEO of Genticel effective immediately. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print